Biology of the TRANCE axis

Cytokine and Growth Factor Reviews

Volumn 14, Issue 3-4, 2003, Pages 251-263

  Walsh, Matthew C ^a   Choi, Yongwon ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dendritic cell; Osteoclastogenesis; Osteoimmunology; T lymphocyte; Tolerance

Indexed keywords

COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN C FOS; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTHRITIS; BREAST DEVELOPMENT; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SURVIVAL; DENDRITIC CELL; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LACTATION; LYMPH NODE; MAMMARY GLAND FUNCTION; METASTASIS; NONHUMAN; ORGANOGENESIS; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PERIODONTITIS; PREGNANCY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 0037644721     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(03)00027-3     Document Type: Review

References (110)

1. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104(4):487-501.
2. Fesik SW. Insights into programmed cell death through structural biology. Cell 2000;103(2):273-82.
3. Nagata S. Fas-induced apoptosis. Intern Med 1998;37(2):179-81.
4. Chung JY, et al. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002;115(4):679-88.
5. Headon DJ, Overbeek PA. Involvement of a novel Tnf receptor homologue in hair follicle induction. Nat Genet 1999;22(4):370-4.
6. Fu YX, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 1999;17:399-433.
7. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002;20:795-823.
8. Jones DH, Kong YY, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 2002;61(Suppl 2):ii32-9.
9. Simonet WS, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89(2):309-19.
10. Tsuda E, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234(1):137-42.
11. Kwon BS, et al. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998;12(10):845- 54.
12. Yun TJ, et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lympoid cells and is up-regulated by ligating CD40. J Immunol 1998;161(11):6113-21.
13. Thirunavukkarasu K, et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem 2001;276(39):36241-50.
14. Wan M, et al. Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. J Biol Chem 2001;276(13):10119-25.
15. Emery JG. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273(23):14363-7.
16. Truneh A, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000;275(30):23319-25.
17. Atkins GJ, et al. Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone 2002;31(4):448-56.
18. Holen I, et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002;62(6):1619-23.
19. Wong BR, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272(40)125190-4.
20. Anderson DM, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390(6656):175-9.
21. Yasuda H, et al. Osteoclast differentiation factor is a ligand for steoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95(7):3597-602.
22. Lacey DL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93(2):165-76.
23. Nakashima T, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275(3):768-75.
24. Lum L, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274(19):13613-8.
25. Kartsogiannis V, et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999;25(5):525-34.
26. Kitazawa R, Kitazawa S, Maeda S. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochim Biophys Acta 1999;1445(1):134-41.
27. Hsu H, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96(7):3540-5.
28. Damay BG, et al. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem 1998;273(32):20551-5.
29. Galibert L, et al. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem 1998;273(51):34120-7.
30. Ye H, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 2002;418(6896):443-7.
31. Damay BG, et al. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 1999;274(12):7724-31.
32. Naito A, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999;4(6):353-62.
33. Lomaga MA, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999;13(8):1015-24.
34. Takayanagi H, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000;408(6812):600-5.
35. Wong BR, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999;4(6):1041-9.
36. Arron JR, et al. A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. J Biol Chem 2001;276(32):30011-7.
37. Mizukami J, et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol 2002;22(4):992-1000.
38. Hofbauer LC, et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by Vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998;250(3):776-81.
39. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140(8):3552-61.
40. Hofbauer LC, et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999;140(9):4367-70.
41. Hofbauer LC, et al. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25(3):255-9.
42. Palmqvist P, et al. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 2002;169(6):3353-62.
43. Ahlen J, et al. Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. Bone 2002;31(1):242-51.
44. Murakami T, et al. Transforming growth factor-betal increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 1998;252(3):747-52.
45. Quinn JM, et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 2001;16(10):1787-94.
46. Gao YH, et al. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). Biochem Biophys Res Commun 1998;252(3):697-702.
47. Brandstrom H, et al. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. Biochem Biophys Res Commun 1998;247(2):338-41.
48. Takami M, et al. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Endocrinology 2000;141(12):4711-9.
49. Rubin J, et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 2002;87(9):4273-9.
50. Hofbauer LC, et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001;280(1):334-9.
51. Wang R, et al. Regulation of activation-induced receptor activator of NF-kappaB ligand (RANKL) expression in T cells. Eur J Immunol 2002;32(4):1090-8.
52. Mukohyama H, et al. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. Biochem Biophys Res Commun 2000;271(1):158453.
53. Akiyama H, et al. Indian hedgehog in the late-phase differentiation in mouse chondrogenic EC cells, ATDC5: upregulation of type X collagen and osteoprotegerin ligand mRNAs. Biochem Biophys Res Commun 1999;257(3):814-20.
54. Nagasawa T, et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. Clin Exp Immunol 2002;130(2):338-44.
55. Roodman GD. Cell biology of the osteoclast. Exp Hematol 1999;27(8):1229-41.
56. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991;9(5): 641-50.
57. Grigoriadis AE, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994;266(5184):443-8.
58. Iotsova V, et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997;3(11):1285-9.
59. Franzoso G, et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997;11(24):3482-96.
60. Yoshida H, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990;345(6274):442-4.
61. Soriano P, et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64(4):693-702.
62. Boyce BF, et al. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992;90(4):1622-7.
63. Bucay N, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12(9):1260-8.
64. Hakeda YY, et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun 1998;251(3):796-801.
65. Kong YY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397(6717):315-23.
66. Dougall WC, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13(18):2412-24.
67. Hughes AE, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000;24(1):45-8.
68. Armstrong AP, et al. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 2002;277(46):44347-56.
69. David JP, et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 2002;115(22):4317-25.
70. Li X, et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 2002;143(8):3105-13.
71. Matsuo K, et al. Fosll is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 2000;24(2):184-7.
72. Takayanagi H, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002;416(6882):744-9.
73. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
74. Kamath AT, et al. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 2002;100(5):1734-41.
75. Stoll S, et al. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 2002;296(5574):1873-6.
76. Miyamoto T, et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001;98(8):2544-54.
77. Yun TJ, et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001;166(3):1482-91.
78. Josien R, et al. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999;162(5):2562-8.
79. Wong BR, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186(12):2075-80.
80. Ouaaz F, et al. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 2002;16(2):257-70.
81. Josien R, et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000;191(3):495-502.
82. Zhong L, et al. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999;29(3):964-72.
83. Bachmann MF, et al. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 1999;189(7):1025-31.
84. Roy M. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol 1993;151(5):2497-510.
85. Cremer I, et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. Blood 2002;100(10):3646-55.
86. Williamson E, Bilsborough JM, Viney JL. Regulation of mucosal dendritic cell function by receptor activator of NF-kappaB (RANK)/RANK ligand interactions: impact on tolerance induction. J Immunol 2002;169(7):3606-12.
87. Green EA, Choi Y, Flavell RA. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002;16(2):183-91.
88. Kong YY, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402(6759):304-9.
89. Horwood NJ, et al. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 2001;166(8):4915-21.
90. Kim N, et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 2000;97(20):10905-10.
91. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
92. Clark WB, Loe H. Mechanisms of initiation and progression of periodontal disease. Periodontology 2000;1993:72-82.
93. Pettit AR, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159(5):1689-99.
94. Teng YT, et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000;106(6):R59-67.
95. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2(8):584-93.
96. Morony S, et al. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-lbeta, TNF- alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res 1999;14(9):1478-85.
97. Sabin FR. The lymphatic system in human embryos, with a consideration of the morphology of the system as a whole. Am J Anat 1909;9:43-91.
98. De Togni P, et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994;264(5159):703-7.
99. Rennert PD, et al. Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity 1998;9(1): 71-9.
100. - cells in lymphoid organ development. Immunol Rev 2002;189(1):41-50.
101. Kim D, et al. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med 2000;192(10):1467-78.
102. + cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity 1997;7(4):493-504.
103. Sun Z, et al. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science 2000;288(5475):2369-73.
104. Yokota Y, et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 1999;397(6721):702-6.
105. Robinson GW, Hennighausen L, Johnson PF. Side-branching in the mammary gland: the progesterone-Wnt connection. Genes Dev 2000;14(8):889-94.
106. Fata JE, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000;103(1):41-50.
107. Cao Y, et al. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 2001;107(6):763-75.
108. Sicinski P, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995;82(4):621-30.
109. Kim HJ, et al. Osteoprotegerin ligand induces beta-case in gene expression through the transcription factor CCAAT/enhancer-binding protein beta. J Biol Chem 2002;277(7):5339-44.
110. Yoshida H, et al. Different cytokines induce surface lymphotoxin-alphabeta on IL-7 receptor-alpha cells that differentially engender lymph nodes and Peyer's patches. Immunity 2002;17:823-33.